Resolution of the Expert Meeting on Increasing the Availability of Innovative Treatments for Patients With Spondyloarthritis

Насонов, Е. Л.; Мазуров, В. И.; Лила, А. М.; Эрдес, Ш. Ф.; Каратеев, Дмитрий Евгеньевич; Верткин, А. Л.; Зырянов, С. К.; Дубиков, А. И.; Frolov, M. Yu.; Обухова, О. В.

doi:10.14412/1995-4484-2017-457-459

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Сообщество ревматологов давно признало, что хронические системные воспалительные ревматические заболевания (РЗ), такие как ревматоидный артрит (РА), системная красная волчанка (СКВ), анкилозирующий спондилит (АС), псориатический артрит (ПсА), васкулиты, подагра, сопровождаются повышенной частотой развития сердечно-сосудистой патологии и кардиоваскулярной смертности [1,2]. Вероятность развития инфаркта миокарда (ИМ) [3,4] и недостаточности кровообращения у больных РА [5] и СКВ [6][7][8] превышает общепопуляционную в 2 раза, при АС -в 1,3-2,2 раза [9][10][11].…”

Section: õðîíè÷åñêèå âîñïàëèòåëüíûå çàáîëåâàíèÿ è ñåðäå÷íî-ñîñóäèñòàÿ ïàòîëîãèÿunclassified

Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

Заводовский¹,

Sivordova²

2018

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Rheumatic diseases (RD), such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, vasculitis, gout are associated with increase in cardiovascular morbidity and mortality. The main causes of increased cardiovascular risk are inflammatory heart and vascular lesions, accelerated progression of atherosclerosis and side effects of drug therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in clinical practice and are on the list of the most prescribed medications. It is known that NSAIDs have a negative effect on the cardiovascular system (CVS). However NSAIDs may decrease the intensity of inflammation, which is an independent risk risk factor for CVS pathology. Therefore in patients with RD it is theoretically possible to reduce the severity of cardiovascular side effects when using NSAIDs. The article discusses the issues of NSAID’s cardiovascular safety, the molecular mechanisms underlying the negative effect of them on CVS, critically evaluated the results of main studies concerning the cardiovascular safety of NSAIDs in chronic inflammatory diseases.

show abstract

Section: õðîíè÷åñêèå âîñïàëèòåëüíûå çàáîëåâàíèÿ è ñåðäå÷íî-ñîñóäèñòàÿ ïàòîëîãèÿunclassified

Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

Заводовский¹,

Sivordova²

2018

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis

Заводовский¹,

Sivordova²,

Polyakova³

et al. 2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To evaluate the effectiveness and tolerability of the drug in patients with undifferentiated peripheral inflammatory arthritis (UPIA). Materials and methods. We observed 60 patients (39 women and 21 men) met G. Hazlewood et al., UPIA criteria, 2011. Patients were divided into 3 groups: with monoarthritis, oligoarthritis and polyarthritis. They took aceclofenac 100 mg twice day for 3 weeks. Results. We noted significant decreasing in pain level according to visual analogue scale: in patients with monoarthritis by 69.3 mm (p0.001); in oligoarthritis group by 47.5 mm (p0.001), in patients with polyarthritis by 30 mm (p0.001). The life quality by the EQ-5D-5L index was improved too in all groups from 0.616 to 0.829 (p0.001). The satisfaction with the therapy was: in monoarthritis patients (80% of patients and 93% of doctors noted good results), in oligoarthritis group (53% and 39% accordingly) and polyarthritis (74% and 64% respectively). We suppose the difference was due to the fact that mono- and oligoarthritis patients suffered from initial forms of seronegative spondylarthropathy, in which the effectiveness of NSAIDs is traditionally higher; polyarthritis patients probably had debut of rheumatoid arthritis. Adverse events of therapy were mild. We noted gastrointestinal tract symptoms (dyspepsia) and increased ALT in 10 patients and increased blood pressure in 1 patient. The symptoms did not require discontinuation of therapy. Сonclusion. Post-registration observational study of first Russian generic aceclofenac (Alental, Vertex, Russia) was conducted. In UPIA patients aceclofenac therapy was most effective in mono- and oligoarthritis patients. The first Russian generic aceclofenac (Alental, Vertex, Russia) has good efficacy, tolerability and safety and can be recommended for arthritis treatment.

show abstract

Resolution of the Expert Meeting on Increasing the Availability of Innovative Treatments for Patients With Spondyloarthritis

Abstract: .

Cited by 2 publications

References 0 publications

Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis

Contact Info

Product

Resources

About